CANY
FULC icon

Caxton Associates (New York)’s Fulcrum Therapeutics FULC Stock Holding History

Caxton Associates (New York)’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,875
Closed -$117K – 567
2024
Q2 		$117K Buy
+18,875
New +$143K ﹤0.01% 459

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Caxton Associates (New York)'s FULC Position: Q3 2024 in Review

Caxton Associates (New York) sold out of Fulcrum Therapeutics (FULC) in Q3 2024, closing a stake of 18,875 shares — an estimated $117K sold.

Caxton Associates (New York) first reported a position in FULC in Q2 2024 and held it in 1 quarter. The position peaked at $117K in Q2 2024. 130 funds tracked by Wall St. Rank hold FULC as of Q3 2024.

  • Caxton Associates (New York) reported no remaining Fulcrum Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 18,875 Fulcrum Therapeutics shares in Q3 2024, an estimated $117K.
  • Caxton Associates (New York) first reported a position in Fulcrum Therapeutics in Q2 2024 and held it in 1 quarter.
  • Caxton Associates (New York)'s Fulcrum Therapeutics position peaked at $117K in Q2 2024.
  • 130 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2024.

Based on Caxton Associates (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.